CardioDx raises $21 million in new funding
Augmenix, developer of hydrogel-based radiation oncology products, closes $10.8M in Series D fundraising
Allergan announces earnings and restructuring/layoffs, while still fighting Valeant
AbbVie and Shire - latest on the merger
Visit our sites for b2b sales and banking employees:
Submit an article to cafepharma's CP Wire. Click here to find out more.
| Company | Average | Last 24h |
Increase |
|---|---|---|---|
| Diagnos | 1 | 8 | 700 % |
| Ranbaxy | 3 | 20 | 567 % |
| Qiagen | 1 | 6 | 500 % |
| Validus | 1 | 6 | 500 % |
| Mallinckrodt | 1 | 5 | 400 % |
| Aglos Pharmaceuticals | 1 | 5 | 400 % |
| Agios Pharmaceuticals | 1 | 5 | 400 % |
| Biomet | 1 | 4 | 300 % |
| Royalty Pharma | 1 | 4 | 300 % |
| Abaxis | 1 | 4 | 300 % |
| Company | Average | Last 24 hrs |
Increase |
|---|---|---|---|
| ONYX Pharmaceuticals | 3 | 35 | 1067 % |
| NovaBay Pharmaceuticals | 1 | 9 | 800 % |
| Keryx | 12 | 100 | 733 % |
| Abaxis | 7 | 46 | 557 % |
| AtriCure | 8 | 50 | 525 % |
| Acura Pharmaceuticals | 1 | 6 | 500 % |
| Pacific Biosciences | 5 | 30 | 500 % |
| CardioDx | 5 | 29 | 480 % |
| BioDrain | 1 | 5 | 400 % |
| Calgary Scientific | 1 | 5 | 400 % |